Cardinal Health, Inc. 10-Q Summary: Quarter Ended September 30, 1995
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended September 30, 1995 (first quarter of fiscal 1996). Cardinal Health, Inc. operates as a wholesale drug distributor. The company is currently engaged in significant consolidation activities, including the ongoing merger with Whitmire Distribution Corporation and a newly announced definitive merger agreement with Medicine Shoppe International, Inc.
Key Financial Metrics
| Metric | Q1 1996 (Sep 30, 1995) | Q1 1995 (Sep 30, 1994) |
|---|---|---|
| Net Sales | $2,033,034,000 | $1,818,687,000 |
| Gross Margin | $118,247,000 (5.82%) | $103,357,000 (5.68%) |
| Operating Earnings | $38,407,000 | $31,156,000 |
| Net Earnings | $20,527,000 | $16,025,000 |
| Diluted EPS | $0.48 | $0.39 |
| Cash and Equivalents | $42,729,000 | $126,781,000 (End of prior year) |
| Net Working Capital | $616,900,000 | $601,300,000 (June 30, 1995) |
| Bank Notes Payable | $19,800,000 | $3,000,000 (June 30, 1995) |
Cash Flow: Net cash used in operating activities was $6,490,000, compared to $33,988,000 provided in the prior year. This shift was driven by increases in trade receivables ($53.8 million) and inventories ($48.9 million), partially offset by an increase in accounts payable ($71.9 million).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12% year-over-year, attributed entirely to internal growth, new customer acquisition, and price increases.
- Margin Expansion: Gross margin percentage improved to 5.82% from 5.68%, driven by growth in higher-margin specialty businesses and expanded marketing programs.
- Expense Efficiency: Selling, general, and administrative (SG&A) expenses decreased as a percentage of sales to 3.93% from 3.97%, due to economies of scale and consolidation of distribution functions.
- Liquidity Shift: While net working capital increased, cash and equivalents declined significantly from the prior year-end due to seasonal inventory buildup and receivables growth, funded by an increase in short-term bank borrowings.
Outlook, Risks, and Unusual Items
- Mergers and Acquisitions:
- Whitmire: The company incurred $3.0 million in merger costs this quarter, with total costs to date of $29.9 million. An additional $6.0 million is expected to be incurred in fiscal 1996.
- Medicine Shoppe: On August 26, 1995, Cardinal signed a definitive merger agreement to acquire Medicine Shoppe International, Inc. The transaction is expected to be accounted for as a pooling-of-interests and will involve issuing between 6.0 and 6.8 million Cardinal shares. A shareholder vote is scheduled for November 13, 1995.
- Legal Proceedings: Cardinal and Whitmire are defendants in consolidated antitrust class action lawsuits ("Brand Name Prescription Drug Litigation"). Management believes the allegations are without merit and does not anticipate a material adverse effect on financial condition.
- Capital Resources: The company maintains $325 million in line-of-credit arrangements ($100 million committed) and has shelf registration capacity to offer up to $200 million in debt securities.
Investor Verification Checklist
- Verify the final terms and shareholder approval status of the Medicine Shoppe merger, specifically the share exchange ratio and potential dilution.
- Monitor the timing and total cost of the Whitmire merger integration, as $6.0 million in costs remain to be incurred.
- Assess the sustainability of the 12% sales growth rate and the ability to maintain gross margin expansion in a competitive wholesale environment.
- Review the impact of seasonal inventory and receivables buildup on future operating cash flows and short-term borrowing requirements.
- Track developments in the Brand Name Prescription Drug Litigation for any unexpected legal settlements or judgments.